Cassava Sciences Study Results of Sumifilam for Alzheimer's Disease
Prohost is happy to inform our subscribers that our positive opinion about Cassava Sciences' product created and developed for Alzheimer’s disease happens to be right.
Cassava Sciences (SAVA) announced today the final results of a Phase 2b study with its lead drug candidate, sumifilam, in Alzheimer’s disease. The results . . .
This content is for paid subscribers.
Today’s Highlights September 14, 2020